Brimochol PF achieves endpoints in phase 3 presbyopia trial

Brimochol PF, a once-daily eye drop under evaluation for the treatment of presbyopia, achieved primary and secondary endpoints in the pivotal phase 3 BRIO-I clinical trial, according to a press release from Visus Therapeutics.

Related Keywords

Ben Bergo , Christine Klimanskis , , Breaking News , Visus Therapeutics ,